DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1580)

Category

1580 Biopharma Reports

    Decision Resources Group (DRG) estimates that 80% of the more than 3 million...
    Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United Kingdom) suffer from comorbid cognitive impairment, which can negatively affect patients’ quality...
    Given the safety and tolerability profiles associated with current osteoporosis...
    Given the safety and tolerability profiles associated with current osteoporosis therapies, as well as the low drug-treatment and compliance rates, significant unmet need remains in the field of osteoporosis. A number of novel osteoporosis therapies are set to launch over the next five years, and it...
    Due to rising antibiotic resistance rates, powerful antibiotics historically...
    Due to rising antibiotic resistance rates, powerful antibiotics historically reserved for later lines of therapy are becoming standard-of-care treatment for gram-negative infections (GNIs), particularly those acquired in healthcare facilities (e.g., hospitals, nursing homes, long-term care...
    This section of the Biosimilars Access & Reimbursement module is based on...
    This section of the Biosimilars Access & Reimbursement module is based on insights captured from 60 surveyed U.S. payers and in-depth interviews with 10 EU5 payers. The primary market research was designed to assess payers’ current experience with biosimilars and how they expect to...
    An increasing number of clinically unique disease-modifying therapies (DMTs)...
    An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS. Nevertheless, all approved drugs present clinical shortcomings, and opportunity lingers for a DMT that...
    In the last ten years, TNF-α inhibitors have transformed the treatment of...
    In the last ten years, TNF-α inhibitors have transformed the treatment of axialspondyloarthritis, including ankylosing spondylitis and nonradiographic axialspondyloarthritis, and have brought new attention to this enigmatic autoimmune disease. Today, a second wave of biological...
    The type 2 diabetes market has become increasingly crowded, with therapies...
    The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S. endocrinologists, primary care physicians, and managed care organization medical/pharmacy directors, this content...
    In every disease market, a detailed understanding of unmet need is required to...
    In every disease market, a detailed understanding of unmet need is required to properly assess drug development opportunities and the vulnerability of marketed brands to new products.   The Unmet Need 2016 Dashboard consolidates the key components featured within each of your purchased...
    Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by...
    Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive muscle weakness due to the loss of anterior motor neurons. Nearly all cases of SMA are caused by homozygous deletion or mutation of the SMN1 gene. SMA ranges widely in severity, and symptom onset usually...
    Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous,...
    Parkinson’s disease (PD) treatment is complex; the disease is heterogeneous, requiring individualized treatment and frequent adjustments (e.g., in dosing, in regimens) to achieve symptom control throughout a patient’s disease course. Since 2015, a handful of new therapies that address PD...
    Prostate cancer requires a multidisciplinary treatment approach that...
    Prostate cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, hormonal therapy, chemotherapy, bone-metastases-targeted therapy, and, in the United States, immunotherapy. Both urologists and oncologists are involved in the management and treatment of...
    Despite advances in treatment, rates of mortality and hospitalization for...
    Despite advances in treatment, rates of mortality and hospitalization for worsening heart failure remain high among CHF patients, and development of therapies with improved efficacy is one of the greatest unmet needs. Furthermore, given that none of the currently available CHF treatments has proven...
    In an era when healthcare payers are demanding more value for the money they...
    In an era when healthcare payers are demanding more value for the money they spend on health services and pharmaceuticals, managed care organizations increasingly have focused on meeting nationally accepted quality measures that are used to judge their performance and, in turn, that MCOs use to hold...
    Despite the recent launches of several new therapies, adding to the range of...
    Despite the recent launches of several new therapies, adding to the range of pharmacotherapies available for treating PAH and contributing to the complexity of the PAH treatment algorithm, a number of key unmet needs remain. These include novel efficacious therapies for PAH able to prolong survival...
    Malignant melanoma requires a multidisciplinary treatment approach that...
    Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, BRAF-mutation status....
    1 - 20 of 1580